Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Sarepta Therapeutics, Inc.

< Previous 1 2 3 Next >
Sarepta Therapeutics Announces Second Quarter 2025 Financial Results and Recent Corporate Developments
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
Sarepta Therapeutics to Announce Second Quarter 2025 Financial Results
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
FDA Informs Sarepta That It Recommends That Sarepta Remove Its Pause and Resume Shipments of ELEVIDYS for Ambulatory Individuals With Duchenne Muscular Dystrophy
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
Sarepta Therapeutics Provides Clarifying Statement on ELEVIDYS
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
Sarepta Therapeutics Acknowledges CHMP Negative Opinion for ELEVIDYS in the European Union
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
Sarepta Therapeutics Announces Voluntary Pause of ELEVIDYS Shipments in the U.S.
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
Sarepta Therapeutics Provides Statement on ELEVIDYS
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
Sarepta Therapeutics Announces Strategic Restructuring and Pipeline Prioritization Plan to Maintain Long-term, Sustainable Growth and Provides Update on ELEVIDYS Label
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
Sarepta Provides Safety Update for ELEVIDYS and Initiates Steps to Strengthen Safety in Non-Ambulatory Individuals with Duchenne
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
U.S. FDA Grants Platform Technology Designation to the Viral Vector Used in SRP-9003, Sarepta’s Investigational Gene Therapy for the Treatment of Limb Girdle Muscular Dystrophy Type 2E/R4
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
Sarepta Provides Update on UK Dosing in ENVISION Study of ELEVIDYS for the treatment of Duchenne Muscular Dystrophy
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
Sarepta Therapeutics Shares New Protein Expression and Safety Results from ENDEAVOR in Participants 2 Years Old at Time of Treatment
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
Sarepta Therapeutics Presents Data at the American Society of Gene & Cell Therapy Conference, Including Statistically Significant Functional Outcomes for 8- and 9-Year-Old Patients in New Data Analysis of EMBARK Part 2
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
Sarepta Therapeutics Announces Approval in Japan of ELEVIDYS, a Gene Therapy to Treat Duchenne Muscular Dystrophy
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
Sarepta Therapeutics to Present at the BofA Securities Health Care Conference
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
Sarepta Therapeutics Announces First Quarter 2025 Financial Results and Recent Corporate Developments
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
Sarepta Therapeutics to Announce First Quarter 2025 Financial Results
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
Sarepta Therapeutics Announces Pipeline Progress for Multiple Limb-Girdle Muscular Dystrophy Programs
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
Sarepta Therapeutics Provides Update on ELEVIDYS
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
Sarepta Therapeutics Announces Call for Applications for the 8th Annual Route 79, The Duchenne Scholarship Program
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Recent Corporate Developments
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
Sarepta Therapeutics Announces Inaugural $600 Million Senior Secured Revolving Credit Facility
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2024 Financial Results
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
Sarepta Therapeutics Announces Results from Part 2 of the EMBARK Study Demonstrating Sustained Benefits and Disease Stabilization in Ambulatory Individuals with Duchenne Muscular Dystrophy Following Treatment with ELEVIDYS
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2024 Net Product Revenue
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
Sarepta Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
Sarepta Therapeutics Completes Enrollment in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4
From Sarepta Therapeutics, Inc.
Via Business Wire
Tickers SRPT
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.